Results 221 to 230 of about 93,898 (384)

Eosinophilic Sialodochitis: A Rare Comorbidity of Severe Asthma

Journal of Investigational Allergy and Clinical Immunology, 2023
O, González, C, Picado, E, Arismendi, I, Alobid, J, Ramirez, A, Valero, I, Bobolea   +6 more
openaire   +2 more sources

Distinct Roles of IL‐4, IL‐13, and IL‐22 in Human Skin Barrier Dysfunction and Atopic Dermatitis

Allergy, EarlyView.
This study reports the distinct effects of IL‐4, IL‐13, and IL‐22 on bio‐stabilized human skin with intact barriers and immune cells. IL‐4, IL‐13, and IL‐22 upregulate inflammatory mediators, disrupt skin barrier integrity, and reciprocally modulate IL‐4Rα and IL‐22Rα1 receptors.
Paolo D'Avino, Juno Kim, Manru Li, Philipp Gessner, Patrick Westermann, Yagız Pat, Carina Beha, Claudia Traidl‐Hoffmann, Jeremy Bost, Nicolas Gaudenzio, Christoph B. Messner, Cezmi A. Akdis, Yasutaka Mitamura   +12 more
wiley   +1 more source

Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma. [PDF]

Front Immunol
Miguéns-Suárez P, Martelo-Vidal L, Vázquez-Mera S, Blanco-Aparicio M, Calvo-Álvarez U, González-Fernández C, Mosteiro-Añón M, Corbacho-Abelaira D, Hermida-Valverde T, Calvo-Henríquez C, Nieto-Fontarigo JJ, Salgado FJ, González-Barcala FJ.   +12 more
europepmc   +1 more source

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

, 2021
Francesco Menzella, Marco Bonavia, Matteo Bonini, Maria D’Amato, Salvatore Lombardo, Nicola Murgia, Vincenzo Patella, Massimo Triggiani, Girolamo Pelaia   +8 more
openalex   +2 more sources

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions

Allergy, EarlyView.
ABSTRACT Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment ...
Marjolein S. de Bruin‐Weller, Celeste M. Boesjes, Roselie A. Achten, Lisa A. Beck, Alan D. Irvine, Christian Vestergaard, Marlies de Graaf, Femke van Wijk, Daphne S. Bakker, Stephan Weidinger   +9 more
wiley   +1 more source

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.

The Lancet Respiratory Medicine, 2021
A. Menzies-Gow, M. Gurnell, L. Heaney, J. Corren, E. Bel, J. Maspero, T. Harrison, D. Jackson, D. Price, N. Lugogo, J. Kreindler, A. Burden, A. de Giorgio-Miller, K. Padilla, U. Martin, E. Garcia Gil   +15 more
semanticscholar   +1 more source

Identification of key genes predicting the efficacy of mepolizumab in the treatment of severe eosinophilic asthma. [PDF]

Sci Rep
Xinmin P, Jinxia C, Fengyuan L.
europepmc   +1 more source

Management and mechanisms of severe eosinophilic asthma

, 2020
Rahul Shrimanker
openalex   +1 more source

Examining Atopic Dermatitis Through the One Health Concept Lens

Allergy, EarlyView.
ABSTRACT This paper explores the application of the One Health framework to atopic dermatitis (AD), a complex, chronic skin disease, emphasizing interdisciplinary approaches to prevention and management. One Health integrates human, animal, environmental, and plant health, addressing challenges such as antimicrobial resistance, infectious diseases, and
Dijana Minić‐Pantić, Bernadette Abela, Jenni Lehtimäki, Alexander Zink, Erika Jensen‐Jarolim, Antonia Fettelschoss‐Gabriel, Claudia Traidl‐Hoffmann, Johannes Ring, Peter Schmid‐Grendelmeir, Pascal Prélaud, Alain Taïeb   +10 more
wiley   +1 more source

COVID-19, Eosinophils, and Biologicals for Severe Asthma

Frontiers in Allergy, 2022
Lombardi, Carlo, Bagnasco, Diego, Passalacqua, Giovanni   +2 more
openaire   +3 more sources